



Leadership Bios



Jurgi Camblong
Founder and CEO

Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the data-driven medicine movement around the world.

He is a molecular biologist, published in *Cell*, *Science* and *Nature*, has a PhD in life sciences from the University of Geneva, and an EMBA in management of technology from EPFL/HEC Lausanne.

In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz. He has since successfully led the development of the company, listed among the 50 Smartest Companies by *MIT Technology Review*. Jurgi has been a member of the Advisory Council on Digital Transformation to the Swiss government and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.



Lara Hashimoto
SVP - Chief Business
Officer

Lara Hashimoto joined SOPHiA GENETICS in 2020. She started in the industry 20 years ago as a scientist at Roche Pharma based in Basel, Switzerland. She held several positions spanning pharma clinical drug development, business analytics, and strategic marketing in the global organization, as well as sales and operational marketing positions in the Canadian affiliate.

In 2009, Lara moved to Roche Molecular Diagnostics in California as the lifecycle leader responsible for the genomics and oncology IVD product portfolio and pipeline, launching several companion diagnostics globally. Lara then became the general manager of Roche Diagnostics New Zealand Ltd where she grew sales above market for four consecutive years.

Returning to the Bay Area, Lara then joined the newly formed Roche Sequencing Solutions team where she was the vice president responsible for non-invasive prenatal testing and the Nanopore Sequencer before being appointed Chief Commercial Officer.

Growing up in Canada, Lara developed an early interest in understanding the role of genetics in common diseases. This took her from studying the genetics of multiple sclerosis at the University of Western Ontario, to joining the Wellcome Trust Centre for Human Genetics at the University of Oxford, UK.



Philippe Menu
SVP - Chief Medical
Officer

Dr. Philippe Menu, MD, PhD, MBA, brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology and business management consulting. He joined SOPHiA GENETICS in 2020 from McKinsey & Company, where he had spent the last eight years serving dozens of clients in the BioPharma sector, advising global pharmaceutical companies, mid-size players and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases.

Philippe obtained his MD and PhD from the University of Lausanne, and his MBA in life sciences from the Open University Business School.



Ross Muken
SVP - Chief
Financial Officer

Ross Muken joined SOPHiA GENETICS in February 2021. He was most recently the CFO and COO of Click Therapeutics.

Before joining Click, he was Partner, Senior Managing Director, and head of the healthcare services and technology research team at Evercore ISI where he covered more than 50 companies across the healthcare technology and distribution, life science tools and diagnostics, managed care and facilities, and medical supplies and devices subsectors.

Prior to joining Evercore ISI, Ross served as a managing director at Deutsche Bank Securities and spent time in the equity research division of Thomas Weisel Partners. He began his career as an M&A investment banker at Bank of America Securities after earning his BS in business administration, magna cum laude, at Boston University.



Manuela Valente
SVP - Chief People
Officer

Manuela Da Silva Valente is a seasoned human resources executive with more than 20 years' experience working in international companies. Manuela joined SOPHiA GENETICS in January 2019 from IQVIA (formerly Quintiles and IMS Health Inc.), a human data science company, where she held a number of senior human resources roles, including global senior human resources director.

Prior to this, she worked at Outcome Sciences, where she successfully established the European operations and led the organization through an acquisition by Quintiles, a global clinical research organization.

Manuela obtained a bachelor's degree in business administration from the Business Management School of Zurich, and a management and human resources diploma from CEFCO Lausanne. Accustomed to working in fast-paced companies, Manuela has extensive experience in aligning people strategies with business objectives and driving significant organizational and cultural changes by focusing on talent development and employee engagement.



Daan Van Well
SVP - General
Counsel

Daan van Well, LL.M, MBA, has more than 20 years of experience as a lawyer in top-tier private practice, in-house and consulting roles. He has extensive experience in legal, governance, and compliance matters.

Prior to joining SOPHiA GENETICS in June 2019, he was the Head of Legal at PwC in Geneva, Switzerland, where he supported a variety of healthcare and other clients with company mergers and acquisitions, business development, governance, and compliance matters.

Prior to that, after having held several in-house roles, Daan served as corporate secretary for international food retailer Ahold (currently Ahold-Delhaize), listed at the New York Stock Exchange and at AEX Euronext Amsterdam, where he oversaw all corporate activities, corporate finance, and investor relations work.

He started his career as a lawyer at international law firm, Loyens & Loeff in Rotterdam, The Netherlands. Daan holds an LL.M in Dutch civil law from Utrecht University and an executive MBA in management and corporate finance from HEC Lausanne.

In parallel to his legal career, Daan has co-founded low/no-alcohol craft beer company, ABLOC. Daan is an avid cycling enthusiast and loves to go the extra mile.



Zhenyu Xu
SVP - Chief
Scientific Officer

Dr. Zhenyu Xu is a genome scientist with a background in molecular and computational biology. Zhenyu is among the most experienced bioinformaticians in clinical NGS data analysis worldwide.

He joined SOPHiA GENETICS in 2012 and is the leader of the technology team that developed the SOPHiA DDMTM platform – the universal technology platform for data-driven medicine.

Zhenyu holds a master's degree from Cambridge University in computational biology and obtained his PhD at the European Molecular Biology Laboratory, where he focused on the transcriptome landscape of yeast. His PhD work systematically characterized the non-coding transcripts in yeast that lead to the unveiling that, in a majority of cases, transcriptions are bidirectional.



**Melissa
Finocchio**
SVP - Regulatory
& Quality Affairs

Melissa Finocchio is an experienced regulatory and quality professional with more than 20 years of experience in in vitro diagnostics.

Before joining SOPHiA GENETICS in May 2021, she worked for bioMérieux, where she held various positions in product development, project management, complaint handling, labeling, and quality. Having lived and worked in multiple countries, she has experienced first-hand the challenges of cross-cultural communication and international management on a global scale and is passionate about the role of quality in facilitating efficient operations.

She received her undergraduate degree in Engineering Management from the University of Missouri-Rolla (now Missouri University of Science & Technology) and her master's degree in Quality Management from Webster University. She is also an American Society of Quality certified Reliability Engineer and Quality Engineer.